Amgen has reported positive results from its phase 3 VESALIUS-CV trial, which demonstrated that Repatha (evolocumab) ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, ...

A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs ...

THURSDAY, Nov. 13, 2025 (HealthDay News) — A new pill from Merck could change how millions of people treat high cholesterol ...

AUSTIN, Texas and TOKYO, Nov. 14, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cardiovascular Biologics Market Size was valued at approximately USD 2.20 billion in 2024 and is projected ...

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes ...

Esperion faces pressure from emerging oral PCSK9i and CETP inhibitors, which offer superior LDL-c lowering. See why I rate ...

Majesco, the insurance industry's foremost innovator in cloud-native, AI-native software for the P&C and L&AH segments, today announced that it has entered into an agreement to acquire Vitech, a ...

For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications may not be sufficient in helping them reach their target cholesterol levels.

New drugs that lower cholesterol and treat hyperlipidemia are preparing to enter the market. According to The New York Times (NYT) and The Wall Street Journal (WSJ) on the 9th, U.S. pharmaceutical ...

The pill is called enlicitide, and in early studies, it has shown the power to lower levels of “bad” LDL cholesterol by up to ...